CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • May 18th, 2009 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of January 4, 2009 (“Effective Date”), is entered into between La Jolla Pharmaceutical Company, a Delaware corporation having its principal place of business at 6455 Nancy Ridge Drive, San Diego, California 92121 (“La Jolla”) and BioMarin CF Limited, an Irish corporation having its registered place of business at 2 Earlsfort Terrace, Dublin 2, Ireland (“BioMarin CF”).
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 18th, 2009 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 1 (the “Amendment”), dated January 16, 2009, amends that certain Securities Purchase Agreement, dated as of January 4, 2009 (the “Agreement”), by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Purchaser”).
CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] LA JOLLA PHARMACEUTICAL COMPANY SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 18th, 2009 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 4, 2009, is executed by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Purchaser”).
AMENDMENT NO. 1 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • May 18th, 2009 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 1 (the “Amendment”), dated January 16, 2009, amends that certain Development and Commercialization Agreement, dated as of January 4, 2009 (the “Development Agreement”), by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and BioMarin CF Limited, an Irish corporation (“BioMarin CF”).
